Prognostic Value of Mucinous Histology Depends on Microsatellite Instability Status in Patients with Stage III Colon Cancer Treated with Adjuvant FOLFOX Chemotherapy: A Retrospective Cohort Study

被引:0
|
作者
Se Hyun Kim
Sang Joon Shin
Kang Young Lee
Hyunki Kim
Tae Il Kim
Dae Ryong Kang
Hyuk Hur
Byung So Min
Nam Kyu Kim
Hyun Chul Chung
Jae Kyung Roh
Joong Bae Ahn
机构
[1] Yonsei University College of Medicine,Department of Internal Medicine
[2] Yonsei University College of Medicine,Department of Surgery
[3] Yonsei University College of Medicine,Department of Pathology
[4] Yonsei University College of Medicine,Biostatistics Collaboration Unit
[5] Yonsei University College of Medicine,Institute for Cancer Research
来源
关键词
Colon Cancer; Lymphovascular Invasion; Mucinous Adenocarcinoma; Severance Hospital; Independent Poor Prognostic Factor;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:3407 / 3413
页数:6
相关论文
共 50 条
  • [41] IMPACT OF ADJUVANT CHEMOTHERAPY ON SURVIVAL OF PATIENTS WITH STAGE II COLON CANCER: RETROSPECTIVE STUDY
    ElAlfy, Eman
    ElKerm, Yasser
    Zaky, Sameh
    Kandil, Alaa
    ANNALS OF ONCOLOGY, 2011, 22 : v117 - v118
  • [42] Impact of Adjuvant Chemotherapy on Survival of Patients With Stage II Colon Cancer - Retrospective Study
    ElAlfy, E.
    El Kerm, Y.
    Kandil, A.
    Zaky, S.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S440 - S440
  • [43] IMPACT OF ADJUVANT CHEMOTHERAPY ON SURVIVAL OF PATIENTS WITH STAGE II COLON CANCER: RETROSPECTIVE STUDY
    El Alfy, E. S.
    Kandil, A. S.
    Zaki, S. I.
    El Kerm, Y. M.
    ANNALS OF ONCOLOGY, 2010, 21 : 221 - 221
  • [44] Impact of Relative Dose Intensity of FOLFOX Adjuvant Chemotherapy on Risk of Death Among Stage III Colon Cancer Patients
    Zhou, Meijiao
    Thompson, Trevor D.
    Lin, Hui-Yi
    Chen, Vivien W.
    Karlitz, Jordan J.
    Fontham, Elizabeth T. H.
    Theall, Katherine P.
    Zhang, Lu
    Hsieh, Mei-Chin
    Pollack, Lori A.
    Wu, Xiao-Cheng
    CLINICAL COLORECTAL CANCER, 2022, 21 (02) : E62 - E75
  • [45] Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy A Pooled Analysis From 2 Randomized Clinical Trials
    Zaanan, Aziz
    Shi, Qian
    Taieb, Julien
    Alberts, Steven R.
    Meyers, Jeffrey P.
    Smyrk, Thomas C.
    Julie, Catherine
    Zawadi, Ayman
    Tabernero, Josep
    Mini, Enrico
    Goldberg, Richard M.
    Folprecht, Gunnar
    Van Laethem, Jean Luc
    Le Malicot, Karine
    Sargent, Daniel J.
    Laurent-Puig, Pierre
    Sinicrope, Frank A.
    JAMA ONCOLOGY, 2018, 4 (03) : 379 - 383
  • [46] Administration of adjuvant chemotherapy in older patients with Stage III colon cancer: an observational study
    van den Broek, C. B. M.
    Puylaert, C. C. E. M.
    Breugom, A. J.
    Bastiaannet, E.
    de Craen, A. J. M.
    van de Velde, C. J. H.
    Liefers, G. -J.
    Portielje, J. E. A.
    COLORECTAL DISEASE, 2017, 19 (10) : O358 - O364
  • [48] Prognostic Impact of Deficient DNA Mismatch Repair in Patients With Stage III Colon Cancer From a Randomized Trial of FOLFOX-Based Adjuvant Chemotherapy
    Sinicrope, Frank A.
    Mahoney, Michelle R.
    Smyrk, Thomas C.
    Thibodeau, Stephen N.
    Warren, Robert S.
    Bertagnolli, Monica M.
    Nelson, Garth D.
    Goldberg, Richard M.
    Sargent, Daniel J.
    Alberts, Steven R.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (29) : 3664 - +
  • [49] Comparison of adjuvant FOLFOX4 chemotherapy and oral UFUR/LV following adjuvant FOLFOX4 chemotherapy in patients with stage III colon cancer subsequent to radical resection
    Huang, Ming-Yii
    Huang, Chun-Ming
    Tsai, Hsiang-Lin
    Huang, Ching-Wen
    Hsieh, Hui-Min
    Yeh, Yung-Sung
    Wu, Jeng-Yih
    Wang, Wen-Ming
    Wang, Jaw-Yuan
    ONCOLOGY LETTERS, 2017, 14 (06) : 6754 - 6762
  • [50] Glycemic Variability in Patients With Stage II-III Colon Cancer Treated With Surgery and Adjuvant Chemotherapy
    Mandolfo, Natalie Rasmussen
    Berger, Ann M.
    Struwe, Leeza A.
    Shade, Marcia Y.
    Goldner, Whitney
    Klute, Kelsey
    Langenfeld, Sean J.
    Hammer, Marilyn J.
    ONCOLOGY NURSING FORUM, 2022, 49 (06) : 571 - 584